Delaware SUPPORT Office Based Opioid Treatment (OBOT) Fellowship - Practice Implementation Track
Delaware has the second highest rate of drug overdose in the country; of those overdose deaths, 88% involved opioids. Further, in Delaware, 61 opioid prescriptions are written for every 100 residents. Delaware also ranks first in the country for high-dose and long acting-opioid prescriptions, both of which increase the risk of OUD and overdose. One of the most effective interventions to reduce opioid related mortality is the delivery of evidence-based treatment including medication for opioid use disorder. Like most states, Delaware does not have sufficient treatment capacity for opioid use disorder. Because there are too few addiction medicine specialists, it is critical that primary care, women's health, and infectious disease specialists who are seeing patients in the community increase their confidence and training to be able to identify and treat opioid use disorder. A variety of barriers have been identified as contributors to buprenorphine underutilization including: insufficient training, education and experience; lack of institutional and clinician peer support; poor care coordination; provider stigma; inadequate or burdensome reimbursement; and burdensome regulatory procedures. Increasing office based opioid treatment (OBOT) in Delaware will lead to an increase in access to opioid use disorder treatment. Delaware Medicaid has received a grant from the Center for Medicare and Medicaid Services to improve addiction treatment capacity.
The OBOT Fellowship administrative track is designed to educate administrators on identification of opioid use disorder and process involved with OBOT. We are utilizing self-paced courses as the first component. In addition, the webinars that will be provided over the 6 month period are designed to foster a Delaware based learning collaborative. For the self-paced courses, we are going to touch upon the following topics: Orientation to Substance Use Disorder and Medication for Opioid Use Disorder (MOUD); Team-Based Care for OBOT; Developing external partnerships; and Quality Assurance and Improvement for OBOT.
To increase the number of waivered providers and the buprenorphine prescribing rates among providers accepting Medicaid in Delaware, we will offer an OBOT (office based opioid treatment) Fellowship program that includes tailored training and technical assistance (TA) to Delaware-based 24 administrators and clinicians . The OBOT features an self-paced web-based training followed by a facilitated learning collaborative. The OBOT includes a clinical and administrative track.
This activity is designed for clinic administrators.
Elements of Competence
This CE activity has been designed to improve learner competence and performance and focuses on the American Board of Medical Specialties' areas of patient care and procedural skills and medical knowledge.
This activity focuses on the Interprofessional competencies of roles/responsibilities, interprofessional communication, and teams/teamwork.
This activity also focuses on the Institute of Medicine competencies of provide patient-centered care; work in interdisciplinary teams and employ evidence-based practice.
At the conclusion of the activity, the administrative healthcare team members will be able to:
- Explain the diagnostic criteria for Substance Use Disorder (SUD) and Medication for Opioid Use Disorder (MOUD)
- Describe the administrative tools needed to successfully implement a team-based care for Office-based Opioid Treatment (OBOT) program
- Explain the process for implementing a quality assurance and improvement effort for their OBOT program.
- Effectively utilize a Delaware-based learning collaborative to develop external partnerships and support team-based care for OBOT.
Orientation to Substance Use Disorder (SUD) & Medication for Opioid Use Disorder (MOUD) (Clinical Admin)
Team-based care for Office Based Opioid Treatment (OBOT) (Clinical Admin)
Partnering with Support Services (Clinical Admin)
Quality Assurance and Improvement for OBOT (Clinical Admin)
*The 6 months of Technical Assistance (TA) will occur from April-September 2021.
This is a virtual conference (eastern time). Please see the Program for further information.
A link will be sent to participants prior to the activity start date.
Clinical Director/Planning Committee Chair(s):
Krishna Winfrey, BS, Principal Researcher
Maliha Ali, MBBS, DrPH, Researcher
Quy Nhi Cap, MPH, Researcher
Daniel Harwell, MS, Researcher
Sarah Mossburg, BSN, MS, PhD, Researcher
Elizabeth Salisbury-Afshar,MD, MPH, FAAFP, FACPM, DFASAM
Mishka Terplan, MD MPH FACOG DFASAM
Claire Viscione, BS, Research Assistant
Additional Committee Members:
Anika Alvanzo, MD, Physician
Amanda Brooks, LCSW CADC, Licensed Clinical Social Worker and Certified Alcohol and Drug Counselor
Kathryn Basques, MSW MSN, APN, PMHMP-BC, Nurse Practitioner
Megan Buresh, MD, Physician
Nicole Michele Gastala, MD, Physician
Terry Horton, MD, FACP, DABAM, Physician
POLICY ON DISCLOSURE
It is the policy of the University of Wisconsin–Madison Interprofessional Continuing Education Partnership (ICEP) that the faculty, authors, planners, and other persons who may influence content of this CE activity disclose all relevant financial relationships with commercial interests* in order to allow CE staff to identify and resolve any potential conflicts of interest. Faculty must also disclose any planned discussions of unlabeled/unapproved uses of drugs or devices during their presentation(s).
For this educational activity, all conflicts of interest have been resolved and detailed disclosures are listed below:
Financial Relationship Disclosures
Discussion of Unlabeled/Unapproved uses of drugs/devices in presentation?
|Maliha Ali, MBBS, DrPH||Committee member||No relevant financial relationships to disclose||No|
|Anika Alvanzo, MD||Speaker/Author||American Society of Addiction Medicine (Fiduciary Officer), Maryland Department of Health and Mental Hygiene (Contractor); Pyramid Healthcare, Inc. (Employment)||No|
|Terese Bailey, BS||Planner||No relevant financial relationships to disclose||No|
|Kathryn Basques, MSW, MSN, APN, PMHMP-BC||Speaker/Author||No relevant financial relationships to disclose||Yes|
|Amanda Brooks, LCSW, CADC||Speaker/Author||No relevant financial relationships to disclose||No|
|Megan Buresh, MD||Speaker/Author||American Society of Addiction Medicine (Contractor)||No|
|Quy Nhi Cap, MPH||Committee Member & Planner||No relevant financial relationships to disclose||No|
|Nicole Gastala, MD||Speaker/Author||No relevant financial relationships to disclose||No|
|Daniel Harwell, MS||Committee Member||No relevant financial relationships to disclose||No|
|Terry Horton, MD, FACP, DABAM||Committee Member||Masimo (Consultant and Advisory Group Member)||No|
|Sarah Mossburg, BSN, MS, PhD||Committee Member||No relevant financial relationships to disclose||No|
|Elizabeth Salsbury-Afshar, MD, MPH, FAAFP, FACPM, DFASAM||Committee Member, Speaker/Author, Content Reviewer||No relevant financial relationships to disclose||No|
|Mishka Terplan, MD, MPH, FACOG, DFASAM||Committee Member, Speaker/Author, Content Reviewer||No relevant financial relationships to disclose||No|
|Claire Viscione, BS||Committee Member||No relevant financial relationships to disclose||No|
|Krishna Winfrey, BS||Committee Member||No relevant financial relationships to disclose||No|
*The ACCME defines a commercial interest as any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. The ACCME does not consider providers of clinical service directly to patients to be commercial interests.
|In support of improving patient care, this activity has been planned and implemented by the University of Wisconsin–Madison Interprofessional Continuing Education Partnership (ICEP) and the American Institutes for Research (AIR). The University of Wisconsin–Madison ICEP is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.|
Credit Designation Statements
American Medical Association (AMA)
The University of Wisconsin–Madison ICEP designates this live activity for a maximum of 4.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
American Nurses Credentialing Center (ANCC)
The University of Wisconsin–Madison ICEP designates this live activity for a maximum of 4.25 ANCC contact hours. ANCC pharmacotherapeutic contact hours will be calculated and awarded as appropriate to meet the needs of advanced practice nurses.
Continuing Education Units (CEUs)
The University of Wisconsin–Madison ICEP, as a member of the University Professional & Continuing Education Association (UPCEA), authorizes this program for .425 continuing education units (CEUs) or 4.25 hours.
Jointly Provided by:
The American Institutes for Research (AIR)
University of Wisconsin–Madison Interprofessional Continuing Education Partnership (ICEP)
- 4.25 AMA PRA Category 1 Credit™
- 4.25 ANCC Contact Hours
- 4.25 University of Wisconsin–Madison Continuing Education Hours
- 4.25 Approved for AMA PRA Category 1 Credit™
Free, current version of Chrome, Firefox, Safari, or Edge. Some older browsers and Internet Explorer could produce error messages or not display the content correctly. Free, current version of Adobe Acrobat Reader or other .pdf reader